Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donor-derived Treg Cells and IL-2 for Refractory cGVHD
NCT06920199Phase 1Recruiting
- Sponsor
- Shanghai General Hospital
- Start
- Jun 2025
- Primary completion
- May 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in chronic graft-versus-host disease (cGVHD), sponsored by Shanghai General Hospital. Primary endpoints: Incidence of Dose-Limiting Toxicity at 28 days and Incidence of Grade 3 and Above Adverse Reactions at 2 years. Started Jun 2025; status: recruiting.
02
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT06920199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06920199.